Latest Depression News

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Actinogen Medical’s XanaMIA Phase 2b/3 trial for Alzheimer’s disease has received a positive safety recommendation from its independent Data Monitoring Committee, allowing the study to proceed unchanged. Investors now await the critical efficacy analysis scheduled for January 2026.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Burgundy Diamond Mines suspends Point Lake operations due to tariff-driven price pressures but extends mine life at Misery and highlights strong economics for Fox Underground.

Bowen Coking Coal maintained steady production and sales in Q3 2025 while slashing costs by a third through a new mining model, despite ongoing administration and receivership. The company generated positive operating cash flow and advanced key development projects.

WOTSO’s flexspace segment sustained growth in Q4 FY25 with a 4% year-on-year revenue increase, opening four new locations and expanding its footprint by 9%. Occupancy dipped slightly but remains robust at 75%.

TrivarX has reported promising interim results from its US veteran-focused mental health trial using ECG technology, while progressing a strategic acquisition of novel brain tumor imaging IP to broaden its diagnostic portfolio.

An application to the Takeovers Panel questions the integrity of Maronan Metals’ recent $16 million placement and its share purchase plan, raising concerns about undisclosed relationships and share price manipulation.

Coronado Global Resources has filed a detailed SEC Form 8-K revealing confidential discussions with noteholders and outlining its growth trajectory, liquidity management, and operational updates across its Australian and US metallurgical coal assets.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

TrivarX has completed recruitment of 60 patients in its US veteran-focused mental health trial, advancing validation of its novel single-lead ECG algorithm for depression screening. Positive interim results from 27 patients set the stage for full data release and commercial discussions.